Navigation Links
FDA Approval for Lung Cancer Treatment -Avastin Along with Chemotherapy

The FDA has approved the drug bevacizumab (Avastin) for first time treatment of advanced lung cancer in conjunction with chemotherapy. // This comes after a large randomised study on lung cancer patients led by Dr.Alan Sandler, lung cancer specialist and director of Thoracic Oncology at Vanderbilt-Ingram Cancer Center.

Nearly 900 patients with non-small cell lung cancer (NSCLC) were tested during the trial. None of them had received any previous chemotherapy. Half were given Avastin along with standard chemotherapy drugs while the others were given chemotherapy alone. The study revealed that patients on Avastin survived an average of two months longer than the usual one year survival rate.

Though this does not sound wonderful, it is important to bear in mind that the results were based on average reactions. In some people the survival was even longer, while in others the tumours shrunk and disappeared. However there was no response in some patients.

Bevacizumab is a targeted drug, which means that it does not attack non-cancerous cells. It acts by stopping development of new blood vessels, which supply the tumours. The side effects are generally mild. However a unique and serious one is bleeding from the primary tumour, since the drug acts on the blood vessels; this has to be addressed.

Dr. Sandler is hopeful that the drug will prove path breaking and lead to better survival rates and also to more patients being cured if the disease is caught early. As NSCLC is the most common form of lung cancer in the US, this is encouraging news indeed.
SRM
'"/>




Page: 1

Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology: